Why is Bafna Pharma. falling/rising?

As of 23-Jul, Bafna Pharmaceuticals Ltd is currently priced at 89.50, reflecting a decrease of 0.93, or 1.03%. The stock has underperformed its sector today by 1.54% and has experienced a trend reversal, falling after two consecutive days of gains. Despite this decline, Bafna Pharmaceuticals has shown strong performance over the past month with a 20.93% increase, and a year-to-date return of 16.99%. However, the stock's delivery volume has significantly decreased by 64.08% compared to the five-day average, indicating falling investor participation. The company maintains a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 1.30 times, and has demonstrated healthy long-term growth with net sales increasing at an annual rate of 27.98%. Additionally, institutional investors have increased their stake by 0.81%, suggesting a positive outlook among more knowledgeable market participants.
In the broader market context, Bafna Pharmaceuticals' short-term performance has been weaker than the benchmark, with a 1-week return of -0.16% compared to the Sensex's gain of 0.11%. While the stock has outperformed the benchmark over the longer term, particularly in the 5-year period with a return of 774.02% versus the Sensex's 116.90%, the recent decline may reflect a correction after a period of strong gains and reduced trading activity. The overall market sentiment appears to be cautious, as indicated by the stock's current underperformance relative to both its sector and the broader market index.